NCT00458900已完成2 期
Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Pharmacokinetics
研究概览
简要总结
In the Intensive Care (IC)-unit moxifloxacin treatment is often started with intravenous administrations. As moxifloxacin is known to have a high oral bioavailability in healthy volunteers, patients are switched to oral or enteral therapy as soon as possible. However, no data on plasma levels for moxifloxacin during such a switch-therapy in IC-patients are available. Therefore, this study aims to evaluate the moxifloxacin-plasma levels and their inter-individual variability during IV to enteral switch therapy in IC-patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •IC patients treated with 400 mg moxifloxacin IV (once a day) that can be switched to enteral administration of 400 mg moxifloxacin.
- •IV steady state
- •Hemodynamic stability
- •Normal enteral feeding without prokinetics
- •Presence of arterial line
- •Informed consent
- •≥ 18 jaar
排除标准
- •Dialysis patients
- •Creatinine clearance < 30 ml/min
- •Transaminase levels > 5x upper limit
研究组 & 干预措施
IV and enteral administration of moxifloxacin
Experimental
IV and enteral administration of moxifloxacin
干预措施: IV and enteral administration of moxifloxacin (Drug)
结局指标
主要结局
Pharmacokinetics
时间窗: 2 days
Pharmacokinetics will be followed.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Pharmacokinetic evaluation of moxifloxacin administered intravenously and orally in healthy volunteers who have had a gastric bypass.Healthy volunteers who have had a gastric bypass at least 6 months agoEUCTR2010-018628-14-BEniversity Ghent
已完成
4 期
Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery PatientsCataractNCT01859702Alcon Research36
已完成
不适用
PK Analysis of Moxifloxacin in the Treatment of CAPPneumoniaNCT01983839University of Aarhus18
终止
1 期
Pharmacokinetic Issues of Moxifloxacin Plus RifapentineMycobacterium TuberculosisNCT00460759Johns Hopkins University15
已完成
3 期
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIsInfectious DiseasesNCT00828971Bayer16